Compare Ginkgo Bioworks Holdings Inc (DNA) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs NICE Ltd — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while NICE Ltd trades at $102.43 (market cap $6.00B). The key difference: NICE Ltd is far larger — about 10.2× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, NICE Ltd nearer its low. Which is the better fit depends on your goals.
| DNA | NICE | |
|---|---|---|
Market Cap | $590.53M | $6.00B |
Sector | Health | Technology |
52-Week High | $16.14 | $170.37 |
52-Week Low | $5.48 | $83.15 |
Enterprise Value | $627.78M | $5.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
NICE stock trades at $103.48, up 3.75% today, with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with a 65.79% gross margin and consistent earnings beats, including Q1 2026 EPS of $2.64 beating expectations of $2.52. Recent news highlights enterprise AI deployments with Banco do Brasil and Sopra Steria, expanding NICE's global footprint in customer experience solutions.
NICE presents a compelling investment case with attractive valuation (P/E 12.13) and 56.5% analyst buy ratings targeting $124.88 consensus. Key risks include execution challenges in AI integration and competitive pressure from larger tech players. The stock's current proximity to 52-week highs requires monitoring for sustainability of recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
